Tender detail
Biosimilars 2026 (GWQ)
Summary
The tender concerns the supply of biosimilar medicines and active-substance-specific rebate agreements to be concluded with pharmaceutical companies. The tender is divided into active-substance-specific lots, and the exact contract and pricing terms must be checked in the tender documents. The machine-readable notice did not include precise qualification, suitability or exclusion requirements; these must be checked in the tender documents.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.